Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics
DAWN Price/Volume Stats
| Current price | $7.93 | 52-week high | $18.07 |
| Prev. close | $8.07 | 52-week low | $7.54 |
| Day low | $7.54 | Volume | 1,270,600 |
| Day high | $7.96 | Avg. volume | 1,182,228 |
| 50-day MA | $10.51 | Dividend yield | N/A |
| 200-day MA | $13.04 | Market Cap | 803.75M |
DAWN Stock Price Chart Interactive Chart >
Day One Biopharmaceuticals, Inc. (DAWN) Company Bio
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Price Returns
| 1-mo | -12.47% |
| 3-mo | N/A |
| 6-mo | -42.54% |
| 1-year | -50.93% |
| 3-year | -24.91% |
| 5-year | N/A |
| YTD | -37.41% |
| 2024 | -13.22% |
| 2023 | -32.16% |
| 2022 | 27.72% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...